Aquaculture and fisheries have provided protein sources for human consumption for a long time, but diseases have induced declines in product benefits and raised concerns, resulting in great losses to these industries in many countries. The overuse of antibiotics for the treatment of diseases has increased the chemical concentrations in culture systems and weakened the natural immunity of aquatic organisms. Concerns regarding the detrimental effects of antibiotics on the environment and human health due to residual antibiotic-related issues encourage the development of reliable, environmental and health safety methods, such as vaccines, probiotics, prebiotics, synbiotics and phytobiotics, for protection against disease and for reducing and possibly eliminating disease occurrence. Immunity has been effectively enhanced by pro-, pre-, and synbiotics, which confer strong protection and reduce the risks associated with stressors and disease outbreaks in culture systems. These agents confer several benefits, including enhancing both host growth and immune responses against pathogens, while sustaining health and environmental stability, and their use is thus widely accepted. Alterations in gene expression in individual cells could serve as an indicator of the immunity and growth rate of aquatic animals after pro-, pre- and synbiotic feeding. This review addresses the potential use of pro, pre- and synbiotics as immunostimulants for improved aquaculture management and environmental health and chronicles the recent insights regarding the application of pro-, pre- and synbiotics with special emphasis on their immunomodulatory and antioxidative responses based on gene expression changes. Furthermore, the current review describes the research gaps and other issues that merit further investigation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.fsi.2019.12.054 | DOI Listing |
Nat Commun
December 2024
Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, SE1 9RT, UK.
The role of myeloid cells in the pathogenesis of SARS-CoV-2 is well established, in particular as drivers of cytokine production and systemic inflammation characteristic of severe COVID-19. However, the potential for myeloid cells to act as bona fide targets of productive SARS-CoV-2 infection, and the specifics of entry, remain unclear. Using a panel of anti-SARS-CoV-2 monoclonal antibodies (mAbs) we performed a detailed assessment of antibody-mediated infection of monocytes/macrophages.
View Article and Find Full Text PDFFront Immunol
December 2024
Barcelona Endothelium Team, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Background: Preeclampsia (PE) is a pregnancy complication characterized by hypertension, proteinuria, endothelial dysfunction, and complement dysregulation. Placenta-derived extracellular vesicles (EVs), necessary in maternal-fetal communication, might contribute to PE pathogenesis. Moreover, neutrophil extracellular traps (NETs) play a pathogenic role in other complement-mediated pathologies, and their contribution in PE remains unexplored.
View Article and Find Full Text PDFPract Radiat Oncol
December 2024
Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA; Harvard Medical School, Boston, MA.
Purpose: Many medical students in the U.S. lack formal exposure to radiation oncology (RO).
View Article and Find Full Text PDFPract Radiat Oncol
December 2024
Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH.
Background And Objective: We evaluate prognostic factors and patterns of recurrence in patients who received RT ± androgen deprivation therapy (ADT) for pathologic node-positive (pN1) prostate cancer (PCa) in a multi-institutional cohort.
Methods: Data from patients with pN1 PCa and received RT with short term (ST, ≤6 mo) or long term (LT, >6 mo) ADT were obtained from 4 academic institutions. Biochemical progression free survival (bPFS) and distant metastasis free survival (DMFS) were evaluated.
Transplant Cell Ther
December 2024
Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA 33612. Electronic address:
Background: Axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T-cell therapy, has significantly improved clinical outcomes in adult patients with relapsed/refractory large B-cell lymphoma (LBCL). However, few studies have examined patient-reported outcomes (PROs) or neurocognitive performance in patients treated with axi-cel. Moreover, no longitudinal PRO study has reported on patients treated with axi-cel as standard of care in the United States, to our knowledge.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!